CTLA4 and sarcoidosis: Granulomatous reactions, including sarcoidosis or sarcoid-like reactions have been associated with anti-CTLA-4 and anti-PD-1/PD-L1 therapy with onset anywhere from two weeks to two years (6, 8, 9).